Matthew Herper on Muck Rack

Matthew Herper Verified

New York
Senior Editor — Forbes
As seen in:  Forbes

Forbes reporter covering science and medicine

New 'Hutch' Director Aims To Push Toward Cancer Cures Based On The Immune System

forbes.com — This morning, the Fred Hutchinson Cancer Research Center in Seattle, a hotbed for the development of new treatments that harness the immune system against cancer, is announcing that it has hired former Merck cancer research boss Gary Gilliland as its next director. "I'm really excited about this," said Gilliland, 60, in [...]

The Forbes Healthcare Summit 2014: The Agenda

forbes.com — I spend a lot of my time this year putting together the agenda for our annual Forbes Healthcare Summit, which will be held this year on December 3 and 4. It's an invite-only event where we gather some of the top minds in health care. This year will feature patients, [...]

Surprise! Vytorin Works. Here Are Five Things You Should Know.

forbes.com — For 12 years, there's been a raging, multibillion controversy in the giant market for cholesterol-lowering drugs taken by 20 million or more Americans: does one set of pills, Zetia and Vytorin from Merck, actually prevent heart attacks or is they, in the memorable words of one top cardiologist, expensive placebos?

After Years Under Attack, Merck's Vytorin Proves Effective

forbes.com — Since 2007, the blockbuster cholesterol pills Zetia and Vytorin have been under a cloud as many doctors questioned their effectiveness at preventing heart attacks - and those questions have caused prescriptions of the pills to fall by more than 50%. Today, that cloud lifts. An 18,000-patient trial shows that Vytorin, which [...]

A Day Of Reckoning Approaches For Merck And Its Critics

forbes.com — Some moments are impossible to prepare for. Rehearse your wedding or the birth of your first child all you want, you'll still be overwhelmed by the moment. The same goes for a bad breakup, or the loss of a loved one. And the same goes, sometimes, for scientific findings: thinking [...]

What Employers Are Doing To Counter Ebola

forbes.com — Ebola has killed over 5,000 people, roiled U.S. hospitals, and shaken the faith of Americans in the government's ability to respond. At the same time, and below the radar, U.S. companies are responding to Ebola with a variety of steps to protect themselves, their employees, and their operations. The most important [...]

Rothberg Returns With Star Trek-Like Medical Device To Create Images And Cut With Sound Waves

forbes.com — When we last left Jonathan Rothberg, the entrepreneur who first throttled DNA sequencing onto its Moore's Law-beating path, he was leaving behind his genetics work behind in the tangle of Thermo Fisher's $14 billion purchase of Life Technologies, which had previously bought his startup, Ion Torrent. Rothberg, one of the most [...]

Auerbach, Yancopoulos To Speak At Forbes Healthcare Summit

forbes.com — Two of the top entrepreneurs in the history of the biotechnology industry will join me at the Forbes Healthcare Summit to discuss how new sources of data will change the way drugs are invented, developed, and priced. Alan Auerbach, the chairman and chief executive of Puma Biotechnology, became one of the [...]

Debate: Do High Drug Prices Drive Innovation, Or Hurt It?

forbes.com — After I wrote about the problems of high cancer drug prices in this space (See: "Could High Drug Prices Be Bad For Innovation"), John LaMattina, the former head of R&D at Pfizer and a regular Forbes contributor, took issue with my arguments. He writes: Dr. Peter B. Bach is [...]

A Question For Sanofi: What About Genzyme?

forbes.com — One thing that has not been mentioned with regard to Sanofi's ouster of CEO Chris Viehbacher: Although he has resigned his directorship and been removed as chief executive, there has been no mention of what happens to Viehbacher's position as chairman of the board at Genzyme, Sanofi's Cambridge, Mass.-based biotech outpost [...]
More Articles →
Nov 21, 2014

RT @zbiotech: didn't see a PR but $MRK anacetrapib 1yr pIII REALIZE HeFH was pretty solid - 40% drop in LDL, 44% vs 5% hit <70mg/dl http://…

Nov 21, 2014

RT @onceuponA: Boehner is suing Obama over the employer mandate delay... and cost-sharing reductions? nyti.ms/1p5Tes0

Nov 21, 2014

RT @zbiotech: at 8wks into launch $OREX % of TRxs attributed to 'assistance programs' total 27% vs 60% at same point for $ARNA

Nov 21, 2014

Awesomesauce: .@realdanlyons Used to be Fake Steve Jobs. Now He's the Chief Valleywag. on.recode.net/1yuoNvT via @pkafka

Nov 20, 2014

Thank God for PBS RT @leonidkruglyak Just when you think the discovery channel can’t sink any lower… slate.com/blogs/wild_thi…

Nov 20, 2014

@jamie_love @bhmunos I don't know that the same is true for orphan oncology products, and think your analysis oversimplifies some.

Nov 20, 2014

@jamie_love I'd guesstimate the cost of an ultra-orphan drug at 60% lower than average NME, w/o tax credit. My guess, not @bhmunos'.

Nov 20, 2014

@jamie_love @bhmunos Jamie, have you done anything on the Orphan Drug tax credit? Incidentally my/Bernard's data support orphans=cheap.

Nov 20, 2014

@jamie_love @bhmunos point taken on "a solid piece of scholarship." No reason it can't be "brave," though.

Learn how to connect with Matthew on social media by joining Muck Rack Pro



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.


Share This Profile